Michael Torres, MD
Psychiatry · Owings Mills, MDNPI 1003842808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 40.7% of the total. Reporting peaked in 2019 at $631 and has fallen 86.3% since, to $86 in 2025.
Across 42 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$411
- Johnson & Johnson$168
- AbbVie$167
- Alkermes, Inc.$54
- Shire North American Group Inc$48
- GSK$47
- plus $115 from 4 others
What the payments were for
- Food & beverage$1,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $411 |
| Johnson & Johnson | 3 | $168 |
| AbbVie | 6 | $167 |
| Alkermes, Inc. | 2 | $54 |
| Shire North American Group Inc | 2 | $48 |
| GSK | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,010 in reported general payments places this provider in the 75th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 64 | $2,051 |
| Clonazepam | 43 | $905 |
| Aripiprazole | 24 | $717 |
| Quetiapine Fumarate | 28 | $645 |
| Escitalopram Oxalate | 34 | $638 |
| Zolpidem Tartrate | 38 | $540 |
| Duloxetine Hcl | 38 | $476 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $238 |
| Lamotrigine | 16 | $192 |
| Alprazolam | 24 | $185 |
| Trazodone Hcl | 35 | $161 |
| Risperidone | 14 | $139 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Owings Mills
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.